Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eragidomide - Celgene Corporation

Next Previous
X
Search
Drug Profile

Eragidomide - Celgene Corporation

Alternative Names: CC-90009; GSPT1 CELMoD

Latest Information Update: 14 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Class Acetamides; Antineoplastics; Chlorobenzenes; Fluorine compounds; Isoindoles; Piperidines; Small molecules
  • Mechanism of Action CRBN protein modulators; Peptide-chain-release factor 3 modulators; Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Phase I Myelodysplastic syndromes

Most Recent Events

  • 30 May 2024 Celgene terminates a phase I/II trial in Acute myeloid leukaemia (Combination therapy) in USA, Belgium, Canada, France, UK (IV) (NCT04336982) due to change in business objectives (NCT04336982)
  • 14 May 2024 Celgene terminates a phase I trial in Myelodysplastic syndromes (Second-line therapy or greater) in Canada, France, Norway, Spain, United Kingdom and USA (IV) because of lack of efficacy in the short term acute phase(NCT02848001)
  • 28 Jul 2022 Eragidomide is still in Myelodysplastic syndromes (Second-line therapy or greater) in Canada, France, Norway, Spain, United Kingdom and USA (IV) (NCT02848001)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top